For the quarter ending 2026-03-31, EVMN had $4,249K increase in cash & cash equivalents over the period. -$27,586K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Net loss | -21,674 | -28,273 | -40,597 |
| Stock-based compensation expense | 3,454 | 4,196 | 1,660 |
| Net amortization of premiums and accretion of discounts on investments | 792 | 585 | 1,184 |
| Depreciation and amortization | 349 | 326 | 1,063 |
| Change in fair value of convertible preferred stock forward | - | 0 | 8,928 |
| Prepaid expenses and other assets | 85 | 372 | 1,998 |
| Accounts payable | -3,749 | 3,851 | -4,688 |
| Accrued liabilities | -4,813 | 4,297 | -1,479 |
| Operating lease liabilities | -193 | -139 | -591 |
| Deferred revenue | - | 0 | -3,000 |
| Net cash used in operating activities | -27,503 | -16,699 | -59,742 |
| Purchases of short-term investments | - | - | 38,775 |
| Purchases of investments | 108,776 | 199,172 | - |
| Maturities of short-term investments | - | - | 46,500 |
| Maturities of investments | 23,500 | 84,100 | - |
| Purchase of property and equipment | 83 | 104 | 131 |
| Net cash (used in) provided by investing activities | -85,359 | -122,901 | 7,594 |
| Proceeds from the sale of common stock in initial public offering, net of offering costs paid | - | 157,284 | - |
| Proceeds from issuance of convertible preferred stock, net of issuance costs | - | 0 | 65,228 |
| Proceeds from private placement financing, net of transaction costs | 117,198 | - | - |
| Proceeds from exercise of stock options | 0 | 0 | 6 |
| Payment of deferred offering costs | - | - | 874 |
| Principal payments of finance lease liability | 87 | 86 | 287 |
| Principal payments of financing obligation | 0 | 0 | 158 |
| Taxes paid related to net share settlement of equity awards | - | 1,224 | - |
| Net cash provided by (used in) financing activities | 117,111 | 156,848 | 63,915 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 4,249 | 17,248 | 11,767 |
| Cash, cash equivalents and restricted cash - beginning of year | 45,478 | 28,230 | 16,463 |
| Cash, cash equivalents and restricted cash - end of year | 49,727 | 45,478 | 28,230 |
Evommune, Inc. (EVMN)
Evommune, Inc. (EVMN)